LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Home・Aandelen Lijst・Moleculin Biotech Inc

M
Moleculin Biotech Inc

Gesloten

2.12 -9.4

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

2.44

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+797.44% upside

Moleculin Biotech Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 mei 2026, 22:54 UTC

Winsten

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 mei 2026, 23:51 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

13 mei 2026, 23:51 UTC

Marktinformatie

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 mei 2026, 23:45 UTC

Marktinformatie

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 mei 2026, 23:45 UTC

Marktinformatie

Global Equities Roundup: Market Talk

13 mei 2026, 23:17 UTC

Winsten

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 mei 2026, 23:16 UTC

Winsten

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 mei 2026, 23:15 UTC

Winsten

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 mei 2026, 23:14 UTC

Winsten

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 mei 2026, 23:02 UTC

Marktinformatie

Winsten

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 mei 2026, 22:59 UTC

Marktinformatie

Winsten

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 mei 2026, 22:24 UTC

Winsten

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 mei 2026, 22:23 UTC

Winsten

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 mei 2026, 22:23 UTC

Winsten

Xero FY International Revenue Growth 47%>XRO.AU

13 mei 2026, 22:22 UTC

Winsten

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 mei 2026, 22:19 UTC

Winsten

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 mei 2026, 22:19 UTC

Winsten

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 mei 2026, 22:18 UTC

Winsten

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 mei 2026, 22:16 UTC

Winsten

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 mei 2026, 22:15 UTC

Winsten

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 mei 2026, 22:15 UTC

Winsten

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 mei 2026, 22:13 UTC

Winsten

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 mei 2026, 22:12 UTC

Winsten

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 mei 2026, 22:11 UTC

Winsten

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 mei 2026, 22:11 UTC

Winsten

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 mei 2026, 22:10 UTC

Winsten

Xero Did Not Declare a Dividend>XRO.AU

13 mei 2026, 22:10 UTC

Winsten

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 mei 2026, 22:09 UTC

Winsten

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 mei 2026, 22:00 UTC

Winsten

Cisco to Shed Jobs for All-In AI Push -- Update

13 mei 2026, 21:11 UTC

Winsten

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Peer Vergelijking

Prijswijziging

Moleculin Biotech Inc Prognose

Koersdoel

By TipRanks

797.44% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 21 USD 797.44%

Hoogste 31 USD

Laagste 10 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Moleculin Biotech Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Gebaseerd op 3 analisten die aandelenratings hebben gegeven aan Moleculin Biotech Inc - Dist in de afgelopen 3 maanden.

Financieel

Andere aandelen uit de sector

LLY

Eli Lilly and Co.

1,015.5

↑ +2.79%

JNJ

Johnson and Johnson

230.41

↑ +2.69%

ABBV

AbbVie Inc

208.54

↑ +0.36%

UNH

UnitedHealth Group Inc

400.53

↑ +1.04%

AZN

AstraZeneca PLC

187.75

↑ +1.77%

M Moleculin Biotech Inc

Overzicht

Wijziging aandelenprijs

Aanbevelingen

Moleculin Biotech Inc Grafiek

Gerelateerd nieuws

Peer Vergelijking

Moleculin Biotech Inc Prognose

Koersdoel

Beoordelingsconsensus

Financieel

Andere aandelen uit de sector

M
Moleculin Biotech Inc